Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27241905 | 0.91 | SLC34A1 (0.54) | — | |
| Phosphoric Acid SCHEMBL9545556 | 0.91 | SLC34A1 (0.67) | — | |
| Phosphoric Acid SCHEMBL27565452 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL7127170 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL8076849 | 0.91 | SLC34A1 (0.54) | — | |
| Phosphoric Acid SCHEMBL5507751 | 0.91 | SLC34A1 (0.54) | — | |
| Phosphoric Acid SCHEMBL3785042 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL7870436 | 0.91 | SLC34A1 (0.64) | — | |
| Phosphoric Acid SCHEMBL5863257 | 0.91 | SLC34A1 (0.64) | — | |
| Phosphoric Acid SCHEMBL967 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160258022-A1 | Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-09-08 | — | — | US | disclosed |
| US-20150087000-A1 | DIAGNOSTIC KITS TO DETECT SP22 AND SP22 ANTIBODIES | U.S. ENVIRONMENTAL PROTECTION AGENCY | 2015-03-26 | — | — | US | disclosed |
| US-20140342926-A1 | Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-11-20 | — | — | US | disclosed |
| US-8497135-B2 | Diagnostic kits to detect SP22 and SP22 antibodies | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130164745-A1 | Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-06-27 | — | — | US | disclosed |
| US-8105594-B2 | Methods for amyloid removal using anti-amyloid antibodies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-31 | — | — | US | disclosed |
| US-20110236927-A1 | GENETICALLY STABILIZED TANDEM GENE DUPLICATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-09-29 | — | — | US | disclosed |
| EP-1349955-B1 | COMMON POLYMORPHISM IN SCN5A IMPLICATED IN DRUG-INDUCED CARDIAC ARRHYTHMIA | UNIV UTAH RES FOUND (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8012932-B2 | Contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds a surface exposed epitope of SP22, and a pharmaceutically acceptable carrier | U.S. ENVIRONMENTAL PROTECTION AGENCY (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110166336-A1 | Identification of New Small RNAs and ORFs of E. Coli as Mediators of Cell and Intercell Regulation | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2011-07-07 | — | — | US | disclosed |
| WO-1995004076-A1 | EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF THE CYTOPLASM WITHOUT LEADER SEQUENCES | CELTRIX PHARMACEUTICALS, INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0592597-A4 | NOVEL MUTAGENESIS METHODS AND COMPOSITIONS. | BERLEX LAB (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0619738-A1 | INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR | COR THERAPEUTICS, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994020138-A1 | RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN AND ITS USE IN VACCINE | THERATECH, INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0592597-A1 | NOVEL MUTAGENESIS METHODS AND COMPOSITIONS | BERLEX LABORATORIES, INC. (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1994004570-A1 | CD40 LIGAND, ANTI CD40 ANTIBODIES, AND SOLUBLE CD40 | SCHERING CORPORATION (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5264565-A | Nucleic acid encoding the D2 /Ml chimeric receptor | AFFYMAX TECHNOLOGIES, N.V. (NL) | 1993-11-23 | — | — | US | disclosed |
| WO-1993016183-A1 | CYCLOPHILIN ASSOCIATED MEMBRANE PROTEINS DNA SEQUENCES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993010805-A1 | INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR | COR THERAPEUTICS, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| WO-1993001282-A1 | NOVEL MUTAGENESIS METHODS AND COMPOSITIONS | BERLEX LABORATORIES, INC. (US) | 1993-01-21 | — | — | WO | disclosed |